贝瑞基因实控人353.5万股被强制变现 此前套现2.47亿元

Core Viewpoint - The announcement from Berry Genomics (000710.SZ) indicates that a significant shareholder, Gao Yang, is facing judicial enforcement on a portion of his shares due to a default in a stock pledge repurchase agreement with Guosen Securities. This situation involves the forced liquidation of 3,535,214 shares, representing approximately 1% of the company's total equity [1][2]. Group 1: Shareholder Information - Gao Yang holds 24,918,297 shares of Berry Genomics, accounting for 7.05% of the total share capital, and is the controlling shareholder [1]. - Initially, Gao Yang held 49,260,600 shares, which was 13.89% of the total equity. Since June 29, 2021, he has cumulatively reduced his holdings by 17,841,500 shares, realizing approximately 247 million yuan [3]. Group 2: Financial Implications - Based on the closing price of 13.96 yuan on November 19, the cash amount from the forced sale of shares is estimated to be around 49.35 million yuan [2]. - The execution of these shares is subject to market conditions and the company's stock price, leading to uncertainties regarding the timing and price of the transaction [2]. Group 3: Company Operations - Berry Genomics has stated that its production and operational status remains normal, and the current situation has not significantly impacted its financial condition or governance structure [2].